Group 1 - The 2025 National Medical Insurance Drug List includes 114 new drugs, with 50 being innovative drugs, showing an overall success rate of 88%, an increase from 76% in 2024 [1] - Nine innovative drugs from the Sci-Tech Innovation Board have been included in the medical insurance list, highlighting the strength and vitality of these companies [1] - The first version of the Commercial Health Insurance Innovative Drug List has been released, complementing the basic medical insurance and providing new possibilities for patients to access cutting-edge treatments [4] Group 2 - Nearly 90% of new drugs approved by Sci-Tech Innovation Board companies have received medical insurance support, indicating a shift towards value realization for these companies [2] - The drug "Junshi Biological's Junshida" is the only domestic PCSK9-targeted drug for patients intolerant to statins, now included in the medical insurance list [2] - The successful renewal negotiations for several innovative drugs confirm their clinical value and market position, benefiting a wider patient population [6][7] Group 3 - Innovative drugs from companies like Baiji Shenzhou and Junshi Biological have been recognized for their clinical value and patient benefits, leading to their inclusion in the medical insurance list [7] - The R&D investment of Sci-Tech Innovation Board companies reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10%, indicating a strong commitment to innovation [7] - The cycle of "R&D investment - innovation results - insurance support - market return - reinvestment in R&D" is being established and strengthened within the industry [7]

Core Viewpoint - Junshi Biosciences (01877) saw a morning increase of over 3%, currently up 3.23% at HKD 24.28, with a trading volume of HKD 3.177 million, following the announcement of new indications for its products being included in the National Medical Insurance Directory [1] Group 1: Product Developments - Junshi Biosciences announced that its product Toripalimab injection (brand name: Tuoyi®, product code: JS001) has received two new indications, and its product Engreitzumab injection (brand name: Junshida®, product code: JS002) has been successfully included in the National Medical Insurance Directory (2025) under the Class B category [1] - The new National Medical Insurance Directory will officially take effect on January 1, 2026 [1] Group 2: Market Position - As of the announcement date, the company has four commercialized products, including Tuoyi®, Adalimumab injection (brand name: Junmaikang®, product code: UBP1211), Dexamethasone Hydrochloride tablets (brand name: Mindewi®, product code: VV116/JT001), and Junshida®, all of which have been included in the National Medical Insurance Directory [1] - Tuoyi® is the only anti-PD-1 monoclonal antibody in the directory that is approved for the treatment of renal cancer, triple-negative breast cancer, and melanoma, with all 12 approved indications in mainland China included in the National Medical Insurance Directory [1] - Junshida® is newly included and is the only domestic PCSK9-targeted drug in the new directory for patients intolerant to statins [1]

Core Viewpoint - Junshi Biosciences (01877) saw a morning increase of over 3%, currently up 3.23% at HKD 24.28, with a trading volume of HKD 3.177 million. The company announced that its products, Toripalimab injection (brand name: Tuoyi, product code: JS001) and Engreztinib injection (brand name: Junshida, product code: JS002), have been included in the National Medical Insurance Catalog (2025) under Category B, effective January 1, 2026 [1]. Group 1 - The company has successfully added two new indications for Toripalimab and has included Engreztinib in the National Medical Insurance Catalog [1]. - All 12 approved indications for Toripalimab in mainland China have been included in the National Medical Insurance Catalog, making it the only anti-PD-1 monoclonal antibody in the catalog for the treatment of renal cancer, triple-negative breast cancer, and melanoma [1]. - Engreztinib is newly included in the catalog and is the only domestic PCSK9-targeted drug for patients intolerant to statins in the new version of the catalog [1].

Core Viewpoint - Shanghai Junshi Biosciences Co., Ltd. has implemented the "2025 Action Plan" to enhance operational efficiency, compliance, and high-quality development, focusing on innovation and expanding its drug pipeline [2][11]. Group 1: Operational Efficiency and Development - The company aims to become a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization [2]. - The company has expanded its innovation areas from monoclonal antibodies to include small molecules, antibody-drug conjugates (ADC), bispecific antibodies, fusion proteins, nucleic acid drugs, and vaccines, targeting next-generation therapies for cancer and autoimmune diseases [2][3]. - As of the report date, the company has four commercialized drugs and nearly 30 drugs in clinical trials, with over 20 in preclinical development [2]. Group 2: Research and Development Achievements - During the reporting period, the company accelerated clinical development, reduced production costs, and improved sales efficiency, achieving a 49.41% year-on-year increase in drug sales revenue to 1.059 billion yuan [6]. - The company received NMPA approval for new indications for its drug Tuoyi, which is now approved for 12 indications in mainland China and has been approved in multiple countries [3][4]. - Clinical research efficiency improved, with over 1,400 participants enrolled in clinical studies [4]. Group 3: Production and Sales - The company has optimized its production system and received GMP certifications in various regions, ensuring stable supply and meeting growing market demand [5]. - The core product Tuoyi achieved sales revenue of 954 million yuan in the domestic market, reflecting a growth of approximately 42% [6]. Group 4: Governance and Compliance - The company has strengthened its governance structure, establishing a compliance committee at the board level to enhance regulatory adherence and operational integrity [9]. - The company emphasizes investor communication and transparency, responding to investor inquiries and providing regular updates on business progress [10]. Group 5: Talent Development and Innovation - The company has focused on talent development, creating a structured career advancement path and enhancing training resources to foster an innovative workforce [7]. - The company has established a complete technical system to improve drug discovery capabilities and has strengthened intellectual property protection, holding 184 authorized patents [7]. Group 6: Shareholder Returns and Market Management - The company is committed to shareholder returns and has initiated a plan for significant share buybacks, with the chairman planning to increase his stake by at least 100 million yuan [8]. - The company has implemented a market value management system to enhance its market perception and investor relations [8].

Core Viewpoint - Sanofi has ceased the supply of its new lipid-lowering drug, Praluent (alirocumab injection), in the Chinese market due to global supply issues and a strategic shift in its cardiovascular market approach [1][4]. Company Summary - Sanofi has officially notified multiple hospitals about the discontinuation of Praluent in China [2]. - Praluent is a PCSK9 inhibitor used for the prevention of cardiovascular events and treatment of primary hypercholesterolemia and mixed dyslipidemia. It was one of the first PCSK9 monoclonal antibodies approved globally, receiving approval in the U.S. in 2015 and entering the Chinese market in 2020 [4]. - The price of Praluent in China was significantly reduced from 1982 RMB to 306 RMB per injection after being included in the national medical insurance [4]. - Despite the withdrawal of Praluent, Sanofi plans to fill the gap in its cardiovascular pipeline by acquiring exclusive rights to Aficamten, a new cardiac myosin inhibitor, in Greater China, and has also secured rights to another investigational drug, Plerixafor [4][5]. Industry Summary - There are currently seven approved PCSK9-targeted products in China, including three from multinational companies and four from domestic firms. The other products include those from Amgen, Novartis, and Innovent Biologics [7]. - Amgen's Repatha (evolocumab) and Innovent's Xinbile (torcetrapib) are among the alternatives available to patients following Praluent's exit [7]. - Sanofi's recent financial report indicated a revenue of 10 billion euros (approximately 11.4 billion USD) for Q2, with a 10.1% growth, and a total revenue of 19.889 billion euros (approximately 22.8 billion USD) for the first half of the year, reflecting a 9.9% increase [8].

Market Performance in Hong Kong - ZhongAn Online (06060) surged over 8%, with a cumulative increase of over 50% this month, benefiting from stablecoin legislation that positively impacts its virtual asset business [1] - Education stocks collectively rose, with China Education Group (0839) up over 5% and New Oriental (9901) up over 2% [1] - Kingsoft (03888) fell over 6% as Q1 revenue missed expectations [1] - Export stocks strengthened, with Shenzhou International (02313) rising nearly 5% amid a U.S. federal court blocking Trump's tariff policy [1] - Gold stocks collectively declined as international gold prices fell to $3,250 [1] - Apple-related stocks rose collectively, with AAC Technologies (02018), Q Technology (01478), and Sunny Optical (02382) each up over 2% [1] - Junshi Biosciences (01877) increased over 6% after receiving approval for two new indications, accelerating clinical progress of its pipeline [1] - XPeng Motors-W (09868) rose over 6% as the new MONA M03 version saw over 12,000 pre-orders within an hour [1] - Pop Mart (09992) increased over 4% as Labubu 3.0 sparked a global phenomenon, with its brand POPOP set to open its first official store [1] - CRO concept stocks strengthened, with WuXi Biologics rising over 8% and WuXi AppTec and Zai Lab each up over 4% following the U.S. International Trade Court's decision to halt Trump's tariffs [1] - Hongteng Precision (06088) rose over 6% as NVIDIA's data center revenue surged over 70%, resolving previous overheating issues [1] - Tongcheng Travel (00780) increased over 4% with accelerated net profit growth in Q1, as institutions remain optimistic about OTA platform performance [1] - WuXi AppTec-B (02126) surged over 20% after the acceptance of a new indication application for Regorafenib [1] Market Performance in U.S. - NVIDIA (NVDA.US) rose nearly 6% after reporting strong Q1 results and projecting shipments of Blackwell Ultra for Q2 of fiscal 2026 [2] - AI software provider C3.ai (AI.US) soared over 12% with Q4 revenue growth of 26% year-over-year, reaching $109 million [2] - Software giant Salesforce (CRM.US) rose nearly 6% after reporting Q1 revenue of $9.8 billion, an 8% year-over-year increase, and raising its full-year revenue guidance [2] - HP Inc. (HPQ.US) fell nearly 15% after lowering its full-year earnings forecast due to increased costs from tariffs, reporting Q2 net revenue of $13.22 billion [2] - Spero Therapeutics (SPRO.US) surged 245% after successful Phase 3 trial results for a urinary tract infection drug [2] - JZXN (JZXN.US) jumped nearly 25% as the company plans to acquire 1,000 bitcoins within the next year [2] - Joby Aviation (JOBY.US) soared over 28% after receiving a $250 million investment from Toyota, which had previously committed a total of $500 million [2] Additional U.S. Market Highlights - Abercrombie & Fitch (ANF.US) rose nearly 15% as its fiscal outlook indicated that tariffs would not impact sales [3] - ZTO Express (ZTO.US) rose over 4.5% with a Q1 net profit growth of 40.9% [5] - Manbang Group (YMM.US) initially rose over 4%, closing up 1.7%, with Q1 operating profit increasing 1.7 times [5] - Tempus AI (TEM.US) fell nearly 20% after a short-seller report questioned its AI capabilities [5]